# Dengue (DEN4CYD) CDC recommendations- tabular CDSS rules (optimal)

Updated on 2023-04-27

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Vaccine** | **#** | **Age1** | **Age2** | **SpecialCondition** | **Immunization record** | | | **MedIndication1** | **MedIndication2** | **MedIndication3** | **Todo1** | **Todo2** | **Todo3** | **Todo4** | **Note-display** | **Note** |
|  |  |  |  |  | **Y/N** | **Dose** | **Adm date** |  |  |  |  |  |  |  |  |  |
| **DEN4CYD(Dengue)** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Minimal age 9 yrs |
| **Regular and catch-up schedule** | | | | | | | | | | | | | | | | |
|  | 1 | >= 9 yrs | <= 16 yrs | Living in dengue endemic areas (Puerto Rico, American Samoa, US Virgin Islands, Federated States of Micronesia, Republic of Marshall Islands, Republic of Palau) AND have lab confirmation of previous dengue infection (seropositive) | N |  |  |  |  |  | Admin 1st dose | Schedule 2nd dose = 6 mon from now | Schedule 3rd dose = 12 mon from now |  |  |  |
| **Special situations** | | | | | | | | | | | | | | | | |
|  | 2 |  |  |  |  |  |  | Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component |  |  | Do not administer |  |  |  |  | Contraindication |
|  | 3 |  |  |  |  |  |  | Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or patient with HIV infection who are severely immunocompromised, HIV infection CD4+ count < 15% or total CD4 cell count of < 200/mm3 |  |  | Do not administer |  |  |  |  | Contraindication |
|  | 4 |  |  |  |  |  |  | Pregnancy |  |  | Admin vaccine only if benefits outweigh risks for an adverse reaction |  |  |  |  | Precaution |
|  | 5 |  |  |  |  |  |  | HIV infection without evidence of severe immunosuppression (HIV infection CD4+ count >= 15% and total CD4 cell count of >= 200/mm3) |  |  | Admin vaccine only if benefits outweigh risks for an adverse reaction |  |  |  |  | Precaution |
|  | 6 |  |  |  |  |  |  | Moderate or severe acute illness with or without fever |  |  | Admin vaccine only if benefits outweigh risks for an adverse reaction |  |  |  |  | Precaution |